Acute Agitation & Aggression Treatment Market Size
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| CAGR | 4.90 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Acute Agitation & Aggression Treatment Market Analysis
The acute agitation and aggression treatment market is expected to register a CAGR of 4.9% during the forecast period.
The COVID-19 pandemic has impacted the market significantly. The COVID-19 pandemic had few major effects on the global market for acute agitation and aggression treatment market. The pandemic has directly affected the production and demand of agitation and aggression drugs. It has disrupted distribution channels and had a financial impact on firms and financial markets. However, the clinical trials have increased, and numerous studies have been conducted to find the impact of COVID-19 on agitation and aggression. For instance, according to the article 'Predictors of Adolescent Resilience During the COVID-19 Pandemic: Cognitive Reappraisal and Humor' published in November 2021, more anxiety, depressive symptoms, sleep disturbances, and proactive aggression were linked to greater COVID-19 impact. This suggests that due to increasing aggression among the target population, the demand for psychotic drugs or other treatments for the management of agitation and aggression increased during the pandemic. Therefore, owing to the mentioned factors, the COVID -19 pandemic has significantly impacted the studied market.
Factors such as a rise in the geriatric population and an increase in agitation in patients, an increase in focus on creating awareness about agitation and aggression, and ongoing research on the development of novel treatments for agitation are expected to fuel the market growth over the forecast period.
The increase in the geriatric population is expected to be a major contributor to the studied market. According to World Health Organization (WHO) data published in October 2021, between 2015 and 2050, the proportion of the world's population over 60 years is predicted to nearly double from 12% to 22%. In 2050, 80% of older people will be living in low- and middle-income countries. This target population is more prone to getting age-related agitation and anger issues. Additionally, this population accounts for dementia, which triggers aggression among them. Thus, the increase in the number of geriatrics demands for the availability of treatment options. Thereby driving the demand for the market studied.
Moreover, continuous product innovation and developments are major contributors to market growth. For instance, in May 2022, the first patient was dosed in the TRANQUILITY II study of acute treatment for agitation in patients with Alzheimer's disease. The TRANQUILITY II study is led by BioXcel Therapeutics and focuses on BXCL501, an orally dissolving thin film formulation of dexmedetomidine. Thus, the developments in the market are anticipated to boost market growth over the analysis period.
Therefore, due to the factors mentioned above, the studied market is anticipated to witness growth during the forecast period. However, the preference for non-pharmacological interventions and social stigma associated with mental illness is predicted to restrain the growth of the market.
Acute Agitation & Aggression Treatment Market Trends
This section covers the major market trends shaping the Acute Agitation & Aggression Treatment Market according to our research experts:
Benzodiazepines Segment is Expected to Witness Growth Over the Forecast Period
Benzodiazepines, generally known as "benzos", are a group of drugs that affect the central nervous system (CNS) and are used for several ailments. They affect the brain's gamma-aminobutyric acid-A (GABA-A) receptors, which are specialized receptors. The brain's nerves become less receptive to a stimulus when benzos connect to these receptors, which provides a calming effect. Thus, given the mechanism of benzos for initiating calmness in agitated patients, it is expected to generate demand for benzodiazepines, driving the growth of the segment.
According to the article 'Pharmacologic Management of Acute Agitation in Youth in the Emergency Department' published in August 2022, the benzodiazepines lorazepam, midazolam, and diazepam are used to treat agitation. They are the preferred class of drugs for treating severe anxiety, substance withdrawal, catatonia, and agitation brought on by substance intoxication (excluding alcohol intoxication due to the higher risk of respiratory depression).
In addition, another article, 'Treatment of Agitation with Lorazepam in Clinical Practice: A Systematic Review' published in February 2021, stated that lorazepam is a benzodiazepine that is widely used for the management of acute agitation. Also, as per the conclusion of the above-mentioned study, lorazepam provides consistent results and is safe to use, and can be a clinically effective means of treating acutely agitated patients. Hence, such instances are expected to create demand for the development and approval of benzodiazepines. That is further expected to contribute to segment growth.
Therefore, owing to the above factors mentioned , the segment is expected to witness growth over the forecast period.
North America is Expected to Dominate the Market Over the Forecast Period
Due to increasing geriatric populations prone to various chronic diseases and continuous product developments, North America is one of the major contributors to the studied market.
A rise in the geriatric population in countries across North America is a major contributor to the studied market in the region. For instance, according to America's Health Rankings Senior Report-2022, about 55.6 million people aged 65 years or more were living in the United States in 2020, and this is estimated to reach 73.1 million by 2030, which will account for 21% of the total population. In addition, according to a press release by the government of Canada in April 2022, the number of people aged 65 or more increased drastically to 7 million between 2016 to 2021, and it is the second largest increase in the past 75 years. This age group in 2021 represented approximately 1 in 5 Canadians (19%), up from 16.9% in 2016. As per the source above, the number of people aged 85 and older in Canada increased to 861,000 in 2021 compared to the last decade, and this number is estimated to triple by 2046. As this population is prone to dementia and dementia-related aggressive disorder, the increase in the number of geriatrics demands the availability of treatment options for the same. Thus, it is expected to drive market growth in the region.
Moreover, development activities such as product launches, acquisitions, mergers, and rise in clinical trials among other activities are driving the overall, market growth. For instance, in July 2022, Impel Pharmaceuticals, a commercial-stage pharmaceutical company developing transformative therapies dosed its first subject in a Phase 2a proof-of-concept study of INP105, nasal olanzapine, a widely used atypical, second-generation antipsychotic. INP105 is being developed as an acute treatment for agitation in persons with autism spectrum disorder (ASD) using Impel's proprietary Precision Olfactory Delivery (POD) technology which delivers drugs to the upper nasal space. Such developments are anticipated to contribute to the market growth over the forecast period.
Therefore, owing to the aforesaid factors, North America is expected to dominate the market over the forecast period.
Acute Agitation & Aggression Treatment Industry Overview
The global acute agitation and aggression treatment market is fragmented due to presence of numerous market players focused on product development and innovation. Companies like Eli Lilly and Company, Pfizer, Inc., Otsuka Holdings, GlaxoSmithKline, H. Lundbeck A/S, Johnson & Johnson, and Bristol-Myers Squibb, among others, hold a substantial market share, among others.
Acute Agitation & Aggression Treatment Market Leaders
-
Eli Lilly and Company
-
H. Lundbeck A/S
-
GSK plc
-
Otsuka Pharmaceutical Co., Ltd.
-
Pfizer, Inc.
*Disclaimer: Major Players sorted in no particular order
Acute Agitation & Aggression Treatment Market News
- In June 2022, H. Lundbeck A/S and Otsuka Pharmaceutical Co., Ltd. declared positive results of the phase III clinical trial of brexpiprazole in the treatment of agitation in patients with Alzheimer's dementia.
- In April 2022, BioXcel Therapeutics, Inc., a biopharmaceutical company, received Food and Drug Administration (FDA) approval for IGALMI (dexmedetomidine) sublingual film for the treatment of acute agitation associated with schizophrenia or bipolar I or II disorder in adults. IGALMI can be self-administered by patients under the supervision of healthcare providers.
Acute Agitation & Aggression Treatment Market Report - Table of Contents
1. INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rise in Geriatric Population and Increase in Agitation in Patients
4.2.2 Increase in Focus on Creating Awareness About Agitation and Aggression
4.2.3 Ongoing Research on the Development of Novel Treatment for Agitation
4.3 Market Restraints
4.3.1 Preference for Non-Pharmacological Interventions
4.3.2 Social Stigma Associated With Mental Illness
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD million)
5.1 By Route of Administration
5.1.1 Oral
5.1.2 Intramuscular
5.1.3 Others
5.2 By Drug Class
5.2.1 Anti-psychotics
5.2.2 Benzodiazepines
5.2.3 Others
5.3 By End Users
5.3.1 Hospitals & Ambulatory Surgical Centers
5.3.2 Psychiatric Care Facilities
5.3.3 Others
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle-East and Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle-East and Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Eli Lilly and Company
6.1.2 Pfizer, Inc.
6.1.3 Otsuka Pharmaceutical Co., Ltd.
6.1.4 GSK plc
6.1.5 H. Lundbeck A/S
6.1.6 Johnson & Johnson
6.1.7 Bristol-Myers Squibb
6.1.8 BioXcel Therapeutics
6.1.9 Lee Pharma Ltd.
6.1.10 Impel Pharmaceuticals
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
Acute Agitation & Aggression Treatment Industry Segmentation
As per the scope of the report, Agitation is generally defined as excessive verbal and/or motor behavior. It can escalate to aggression, which can be either verbal (vicious cursing and threats) or physical (toward objects or people). The Acute Agitation and Aggression Treatment Market is segmented by Route of Administration (Oral, Intramuscular and Others), Drug Class (Anti-psychotics, Benzodiazepines and Others), End Users (Hospitals & Ambulatory Surgical Centers, Psychiatric Care Facilities and Others), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers the value (in USD million) for the above segments.
| By Route of Administration | |
| Oral | |
| Intramuscular | |
| Others |
| By Drug Class | |
| Anti-psychotics | |
| Benzodiazepines | |
| Others |
| By End Users | |
| Hospitals & Ambulatory Surgical Centers | |
| Psychiatric Care Facilities | |
| Others |
| Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Acute Agitation & Aggression Treatment Market Research FAQs
What is the current Global Acute Agitation and Aggression Treatment Market size?
The Global Acute Agitation and Aggression Treatment Market is projected to register a CAGR of 4.90% during the forecast period (2024-2029)
Who are the key players in Global Acute Agitation and Aggression Treatment Market?
Eli Lilly and Company, H. Lundbeck A/S, GSK plc, Otsuka Pharmaceutical Co., Ltd. and Pfizer, Inc. are the major companies operating in the Global Acute Agitation and Aggression Treatment Market.
Which is the fastest growing region in Global Acute Agitation and Aggression Treatment Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Global Acute Agitation and Aggression Treatment Market?
In 2024, the North America accounts for the largest market share in Global Acute Agitation and Aggression Treatment Market.
What years does this Global Acute Agitation and Aggression Treatment Market cover?
The report covers the Global Acute Agitation and Aggression Treatment Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Global Acute Agitation and Aggression Treatment Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Global Acute Agitation and Aggression Treatment Industry Report
Statistics for the 2024 Global Acute Agitation and Aggression Treatment market share, size and revenue growth rate, created by Mordor Intelligenceā¢ Industry Reports. Global Acute Agitation and Aggression Treatment analysis includes a market forecast outlook to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
